	Lincoln Pharmaceuticals has received a patent, which is valid for 20 years, from the Government of India for its liquid diclofenac metered-dose rectal spray, according to an Oct. 22, 2019 press release.

	Along with the patent (IN320894), Lincoln Pharma has all the relevant approvals from the Drug Controller General of India (DCGI) and is looking to launch the product onto the Indian market by January 2020. In addition to the Indian launch, the company is hoping to gain a global patent for the product with the aim of exporting into the African, Latin American, and Southeast Asian markets, among others.

	“Globally, no liquid formulation of diclofenac for rectal administration is available. Lincoln Pharma will be the first company to introduce this novel solution aimed at better patient compliance, rapid drug release, and greater bioavailability,” said Mahendra Patel, managing director, Lincoln Pharma, in the press release. “We have developed this formulation with diclofenac sodium BP 25% W/V [weight/volume], each squirt delivers diclofenac sodium 50 mg, non-steroidal anti-inflammatory agent. Due to this innovation, now patients can get far better results by using diclofenac rectal spray as compared to the existing diclofenac suppository available in the market. We are planning to apply for a global patent for this solution.”

Deals, Development and Manufacturing

Dosage Forms

Drug Delivery

Industry News

Intellectual Property & Patents

PharmTech Europe News

PharmTech News

Regulatory/GMP Compliance

Regulatory/GMP Compliance, Emerging Markets

Supplier News

Lincoln Pharmaceuticals has received a patent, which is valid for 20 years, from the Government of India for its liquid diclofenac metered-dose rectal spray.